1/25/2012 2:57 AM ET
(RTTNews) – Merck KGaA (MKGAY.PK: News) said the European Commission or EC has approved extension of the indication of Rebif, a treatment for relapsing forms of multiple sclerosis or MS. This EC approval, based on REFLEX study results, is for the use of Rebif 44 micrograms three times weekly in patients who have experienced a single demyelinating event, an early sign of the disease, and who are at high risk of converting to MS.
(RTTNews) – Merck KGaA (MKGAY.PK: News) said the European Commission or EC has approved extension of the indication of Rebif, a treatment for relapsing forms of multiple sclerosis or MS. This EC approval, based on REFLEX study results, is for the use of Rebif 44 micrograms three times weekly in patients who have experienced a single demyelinating event, an early sign of the disease, and who are at high risk of converting to MS.
Annalisa Jenkins, Head of Global Drug Development and Medical at the Merck Serono division. “Multiple sclerosis has an initial stage when clinical manifestations are not pronounced but irreversible neurological damage is taking place. Throughout the European Union, neurologists will now be able to prescribe Rebif for patients with early signs of this devastating disease.”
The new labelling for Rebif is valid immediately in all 27 member states of the European Union. The company still invests in discovering and developing treatment options in this area, including active life-cycle management initiatives for Merck’s foundation therapy, Rebif, as well as strengthening its existing and establish new collaborations to advance research and bring innovative solutions to patients living with MS.
..Comments for each blog posting are always appreciated.
Please use the link found below, to leave comments.. .. All comments are moderated to reduce SPAM and bad language
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
– Click to: REGISTER – For our MS weekly e-Newsletter
“Providing You with ‘MS Views and News’, IS What We Do” ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Help us to educate $ DONATE NOW PLEASE $
“MS Views and News” is a 501©(3) Not-For-Profit organization
as recognized by the Internal Revenue Service
All contributions are tax deductible to the fullest extent allowed by law
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
…………………………
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews